
Does Intel Stock Have Room to Grow?
Intel Corporation (NASDAQ:INTC)’s recent innovations, Xeon 6 SoC and Xeon®…
Trailing 12 Months | Fiscal Quarters | |||||
---|---|---|---|---|---|---|
Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
Income Statement | ||||||
Revenue | $13.8M | $18.3M | $15.6M | $3.7M | $4.4M | |
Gross Profit | $10.9M | $15.7M | $10.1M | $3.1M | $2.9M | |
Operating Income | -$43.6M | -$53.4M | -$111.6M | -$14.9M | -$29.2M | |
EBITDA | -$40.2M | -$50.3M | -$107.2M | -$13.5M | -$19.5M | |
Diluted EPS | -$0.82 | -$0.87 | -$1.63 | -$0.24 | -$0.30 |
Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
---|---|---|---|---|---|---|
Balance Sheet | ||||||
Current Assets | $80.6M | $67.5M | $103.1M | $83M | $214.2M | |
Total Assets | $91.1M | $100.3M | $132.6M | $111.6M | $252.9M | |
Current Liabilities | $14.2M | $7.1M | $7.5M | $12.2M | $33.8M | |
Total Liabilities | $25.8M | $27.3M | $37.5M | $63.6M | $142.4M | |
Total Equity | $65.3M | $73M | $95M | $48M | $110.5M | |
Total Debt | $11.7M | $10.3M | $19.7M | -- | -- |
Trailing 12 Months | Fiscal Quarters | |||||
---|---|---|---|---|---|---|
Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
Cash Flow Statement | ||||||
Cash Flow Operations | -$31.5M | -$30.2M | -$88.6M | -$11.6M | -$25.1M | |
Cash From Investing | -$116K | -$11.6M | -$3.9M | -$10.5M | -$1.7M | |
Cash From Financing | $65.9M | $19.7M | $220.6M | $10.1M | $98.1M | |
Free Cash Flow | -$31.7M | -$41.8M | -$92.5M | -$22M | -$26.8M |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
In the current month, LQDA has received 6 Buy ratings 1 Hold ratings, and 0 Sell ratings. The LQDA average analyst price target in the past 3 months is $25.33.
According to analysts, the consensus estimate is that Liquidia share price will rise to $25.33 per share over the next 12 months.
Analysts are divided on their view about Liquidia share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Liquidia is a Sell and believe this share price will drop from its current level to $19.00.
The price target for Liquidia over the next 1-year time period is forecast to be $25.33 according to 7 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
According to Wall Street analysts, the consensus rating for Liquidia is a Buy. 6 of 7 analysts rate the stock a Buy at this time.
You can purchase shares of Liquidia via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Liquidia shares.
Liquidia was last trading at $13.91 per share. This represents the most recent stock quote for Liquidia. Yesterday, Liquidia closed at $14.81 per share.
In order to purchase Liquidia stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Signup to receive the latest stock alerts
Intel Corporation (NASDAQ:INTC)’s recent innovations, Xeon 6 SoC and Xeon®…
For many years, Walmart (NYSE:WMT) has been the world’s largest…
The AI race has heated up significantly but returns on…
Market Cap: $3.6T
P/E Ratio: 39x
Market Cap: $2.8T
P/E Ratio: 32x
Market Cap: $2.6T
P/E Ratio: 36x
Willdan Group [WLDN] is down 3.97% over the past day.
Guardant Health [GH] is up 8.39% over the past day.
Pro-Dex [PDEX] is up 17.54% over the past day.